Combination therapy with anti-HIV-1 antibodies maintains viral suppression

HIV-1-infected individuals require lifelong antiretroviral therapy (ART) because treatment interruption leads to rapid rebound viremia. Here we report on a phase 1b clinical trial in which a combination of 3BNC117 and 10–1074, two potent monoclonal anti-HIV-1 broadly neutralizing antibodies that tar...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Nature
Main Authors: Mendoza, Pilar, Gruell, Henning, Nogueira, Lilian, Pai, Joy A., Butler, Allison L., Millard, Katrina, Lehmann, Clara, Suárez, Isabelle, Oliveira, Thiago Y., Lorenzi, Julio C.C., Cohen, Yehuda Z., Wyen, Christoph, Kümmerle, Tim, Karagounis, Theodora, Lu, Ching-Lan, Handl, Lisa, Unson-O’Brien, Cecilia, Patel, Roshni, Ruping, Carola, Schlotz, Maike, Witmer-Pack, Maggi, Shimeliovich, Irina, Kremer, Gisela, Thomas, Eleonore, Seaton, Kelly E., Horowitz, Jill, West, Anthony P., Bjorkman, Pamela J., Tomaras, Georgia D., Gulick, Roy M., Pfeifer, Nico, Fätkenheuer, Gerd, Seaman, Michael S., Klein, Florian, Caskey, Marina, Nussenzweig, Michel C.
Formato: Artigo
Idioma:Inglês
Publicado em: 2018
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6166473/
https://ncbi.nlm.nih.gov/pubmed/30258136
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41586-018-0531-2
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados